Health Care [ 11/12 ] | Biotechnology [ 66/74 ]
NASDAQ | Common Stock
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials.
In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 25 | -0.43 Decreased by -30.30% | -0.42 Decreased by -2.11% |
| Feb 20, 25 | -0.42 Increased by +10.64% | -0.42 Increased by +0.52% |
| Nov 7, 24 | -0.36 Increased by +12.20% | -0.37 Increased by +2.70% |
| Aug 8, 24 | -0.34 Increased by 0.00% | -0.34 |
| May 9, 24 | -0.33 Increased by +8.33% | -0.39 Increased by +15.38% |
| Feb 22, 24 | -0.47 Decreased by -51.61% | -0.43 Decreased by -9.30% |
| Nov 9, 23 | -0.41 Decreased by -20.59% | -0.40 Decreased by -2.50% |
| Aug 10, 23 | -0.34 Decreased by -6.25% | -0.40 Increased by +15.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -39.66 M Decreased by -31.58% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -34.13 M Decreased by -32.73% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -31.50 M Decreased by -46.71% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -28.52 M Decreased by -44.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 2.25 M Increased by +N/A% | -30.14 M Decreased by -79.95% | Decreased by -1.34 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -25.71 M Decreased by -53.66% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -21.47 M Decreased by -37.24% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -19.73 M Decreased by -36.13% | Decreased by N/A% Decreased by N/A% |